ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium
- Sunday, October 25, 2020, 7:15
- PR Newswire
- Add a comment
HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /PRNewswire/ – ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA’s clinical candidate,…
About the Author
admin has written 20655 stories on this site.